Alexion Pharmaceuticals Inc (ALXN)

124.51
2.71 2.13
NASDAQ : Health Care
Prev Close 127.22
Open 127.22
Day Low/High 124.21 / 127.64
52 Wk Low/High 110.56 / 205.29
Volume 1.48M
Avg Volume 1.63M
Exchange NASDAQ
Shares Outstanding 224.25M
Market Cap 28.53B
EPS 0.70
P/E Ratio 424.07
Div & Yield N.A. (N.A)

Latest News

Alexion Pharmaceuticals Takes Over #117 Spot From Zoetis

Alexion Pharmaceuticals Takes Over #117 Spot From Zoetis

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #117 spot from Zoetis Inc , according to ETF Channel.

Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition

Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition

TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.

Perceptive's Joe Edelman on Sarepta: I Always Believed Exondys Would Be Approved

Perceptive's Joe Edelman on Sarepta: I Always Believed Exondys Would Be Approved

Sarepta's largest shareholder talks about the company's future following FDA approval of its Duchenne muscular dystrophy drug.

Alexion Pharma (ALXN) Stock Gets 'Underperform' Rating at FBR Capital

Alexion Pharma (ALXN) Stock Gets 'Underperform' Rating at FBR Capital

Alexion Pharma (ALXN) stock coverage was started at FBR Capital on Thursday.

(Photo: Business Wire)

(Photo: Business Wire)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of Uncommon Strength, a global campaign to raise awareness of rare diseases through the celebration of the extraordinary resilience and inner strength...

Alexion To Present At Upcoming Investor Conferences

Alexion To Present At Upcoming Investor Conferences

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at two upcoming investor conferences: Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 13, 2016...

Gilead Sinking Stock Price Calls Out for New Rescue Plan

Gilead Sinking Stock Price Calls Out for New Rescue Plan

Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.

European Commission Grants Orphan Drug Designation To ALXN1007 For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD)

European Commission Grants Orphan Drug Designation To ALXN1007 For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a,...

Biogen Is a Takeover Target but Don't Ignore the Risks

Biogen Is a Takeover Target but Don't Ignore the Risks

The big bounce in Biogen's valuation over the past month would likely bake in a good chunk of the upside premium that could come from any takeover offer.

3 Health Care Stocks Pushing The Sector Higher

3 Health Care Stocks Pushing The Sector Higher

TheStreet highlights 3 stocks pushing the health care sector higher today.

Alexion Reports Second Quarter 2016 Results

Alexion Reports Second Quarter 2016 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the second quarter of 2016.

3 Stocks Dragging In The Drugs Industry

3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the health services industry lower today.

Alexion Presents New SBC-103 (rhNAGLU Enzyme) Phase 1/2 Data On Brain MRI And Neurocognitive Assessments In Patients With Mucopolysaccharidosis IIIB (MPS IIIB)

Alexion Presents New SBC-103 (rhNAGLU Enzyme) Phase 1/2 Data On Brain MRI And Neurocognitive Assessments In Patients With Mucopolysaccharidosis IIIB (MPS IIIB)

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that researchers presented new data from an ongoing open-label, Phase 1/2 trial of intravenous (IV) SBC-103 (rhNAGLU enzyme), an investigational enzyme replacement...

Alexion Pharmaceuticals (ALXN) Stock Gets ‘Outperform’ Rating at RBC Capital

Alexion Pharmaceuticals (ALXN) Stock Gets ‘Outperform’ Rating at RBC Capital

Alexion Pharmaceuticals (ALXN) stock was initiated with an "outperform" rating at RBC Captial earlier today as the firm expects the company 'to continue to dominate the rare disease space.'

Alexion Pharmaceuticals To Report Second Quarter 2016 Results On Thursday, July 28, 2016

Alexion Pharmaceuticals To Report Second Quarter 2016 Results On Thursday, July 28, 2016

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 before the US financial markets open.

Alexion (ALXN) Stock Gains on Ratings Upgrade

Alexion (ALXN) Stock Gains on Ratings Upgrade

Alexion (ALXN) stock is increasing in pre-market trading after Credit Suisse upped its rating to 'outperform' given its upside potential.

Analysts' Actions -- Baker Hughes, ConocoPhillips, GameStop, Toll Brothers and More

Analysts' Actions -- Baker Hughes, ConocoPhillips, GameStop, Toll Brothers and More

Here are Monday's top research calls, including an upgrade for GameStop, and downgrades for Baker Hughes, ConocoPhillips and Toll Brothers.

New Data From Phase 3 REGAIN Study Of Eculizumab (Soliris®) In Patients With Refractory Generalized Myasthenia Gravis (gMG) Presented At ICNMD Annual Congress

New Data From Phase 3 REGAIN Study Of Eculizumab (Soliris®) In Patients With Refractory Generalized Myasthenia Gravis (gMG) Presented At ICNMD Annual Congress

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers presented new results from the REGAIN study, a global, placebo-controlled Phase 3 registration trial of eculizumab (Soliris ®) in patients...

The 10 Worst-Performing S&P 500 Stocks in June

The 10 Worst-Performing S&P 500 Stocks in June

Brexit volatility put a major damper on the global markets this month, and investors who owned these 10 S&P 500 stocks saw their profits shrink substantially in June.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

The Brexit-related market pullback has created stock-buying opportunities. Here are 14 more stocks for investors to consider from Morgan Stanley.

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

The U.S. woke up today to the news of a "Brexit" win, which has sent global markets reeling.

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Late-Breaking Data Presented At EHA: All Patients With PNH Treated With Once-Monthly Dosing Of ALXN1210 In Phase 1/2 Study Exhibit Rapid And Sustained Reductions In LDH

Late-Breaking Data Presented At EHA: All Patients With PNH Treated With Once-Monthly Dosing Of ALXN1210 In Phase 1/2 Study Exhibit Rapid And Sustained Reductions In LDH

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that interim data were presented from a Phase 1/2 study of ALXN1210, an investigational, highly innovative longer-acting anti-C5 antibody, in patients with...

Rev's Forum: Don't Be Seduced by the Market's Dark Side

Too many turn bearish too quickly just because they can't find any entry points.

Trader's Daily Notebook: Gusher for Oil Stocks

Big move for biotechs isn't pleasant.